Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.
Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.

Find a Lilly Clinical Trial

16  Enrolling
30  Total Trials
Conditions: Migraine
Trial Name
PIONEER-PEDS2
Drugs: lasmiditan (LY-573144)
Age
6 - 17 years
Phase
III
Conditions: Atopic Dermatitis (Eczema)
Trial Name
ADorable-1
Drugs: Lebrikizumab, Topical corticosteroid
Age
6 months - 17 years
Phase
III
Conditions: Alopecia Areata (hair loss)
Trial Name
BRAVE-AA-PEDS
Drugs: baricitinib
Age
6 - 17 years
Phase
III
Conditions: Atopic Dermatitis (Eczema)
Trial Name
ADorable-2
Drugs: Lebrikizumab
Age
6 months - 18 years
Phase
III
Conditions: Atopic Dermatitis (Eczema)
Drugs: lebrikizumab, topical corticosteroid
Age
≥12 years
Phase
III
Conditions: Migraine
Trial Name
REBUILD-2
Drugs: Galcanezumab
Age
12 - 17 years
Phase
III
Conditions: Migraine
Trial Name
PIONEER-PEDS1
Drugs: lasmiditan (LY-573144)
Age
6 - 17 years
Phase
III
Conditions: Systemic Juvenile Idiopathic Arthritis
Drugs: Baricitinib
Age
1 year - 17 years
Phase
III
Conditions: Migraine
Trial Name
REBUILD-1
Drugs: Galcanezumab
Age
6 - 17 years
Phase
III
Conditions: Crohn's Disease
Trial Name
AMAY
Drugs: Mirikizumab
Age
2 - 17 years
Phase
III
Conditions: Ulcerative Colitis
Trial Name
SHINE-2
Drugs: LY3074828
Age
2 - 17 years
Phase
III
Conditions: Ewing's Sarcoma
Trial Name
CAMPFIRE
Drugs: Abemaciclib (LY2835219)
Age
1 year - 39 years
Phase
II
Conditions: Crohn's Disease
Trial Name
SHINE-ON
Drugs: Mirikizumab
Age
2 - 19 years
Phase
III
Conditions: COVID-19
Trial Name
COV-BARRIER-PEDS
Drugs: Baricitinib, LY3009104
Age
2 - 18 years
Phase
III
Conditions: Obesity
Drugs: Tirzepatide
Age
12 - 17 years
Phase
III
Conditions: Juvenile Idiopathic Arthritis
Trial Name
JUVE-X
Drugs: Baricitinib
Age
1 year - 18 years
Phase
III

Lilly Trial Alerts

Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.
2  Not Yet Enrolling
30  Total Trials
Conditions: Type 2 diabetes
Drugs: LY3209590
Age
10 - 17 years
Phase
I
Conditions: Obesity
Trial Name
SURMOUNT-ADOLESCENTS-2
Drugs: tirzepatide
Age
12 - 17 years
Phase
III
12 
Completed Enrollment
30  Total Trials
Conditions: Advanced Solid Tumors
Drugs: Abemaciclib, Irinotecan, Temozolomide, Dinutuximab and GM-CSF
Age
≤21 years
Phase
II
Conditions: Medullary Thyroid Cancer
Trial Name
LIBRETTO-531
Drugs: Selpercatinib, Cabozantinib, Vandetanib
Age
≥12 years
Phase
III
Conditions: Desmoplastic Small Round Cell Tumor
Trial Name
CAMPFIRE
Drugs: Cyclophosphamide, Ramucirumab, Vinorelbine
Age
12 months - 29 years
Phase
II
Conditions: Atopic Dermatitis (Eczema)
Trial Name
ADmirable
Drugs: Lebrikizumab
Age
≥12 years
Phase
III
Conditions: Atopic Dermatitis (Eczema)
Trial Name
BREEZE-AD-PEDS
Drugs: Baricitinib, Placebo
Age
2 - 17 years
Phase
III
Conditions: Uveitis
Drugs: Baricitinib, Adalimumab
Age
2 - 17 years
Phase
III
Conditions: Aicardi Goutieres Syndrome (AGS)
Drugs: Baricitinib
Age
≥6 months
Phase
III
Conditions: Atopic Dermatitis (Eczema)
Trial Name
ADapt
Drugs: Lebrikizumab
Age
≥12 years
Phase
III
Conditions: Type 2 Diabetes
Trial Name
SURPASS-PEDS
Drugs: Tirzepatide
Age
10 - 18 years
Phase
III
Conditions: Lung Cancer, Thyroid Cancer and other Solid Tumors
Trial Name
JUVE-BASIS
Drugs: LOXO-260
Age
≥12 years
Phase
I
Conditions: Neuroblastoma
Drugs: LY3295668 Erbumine, Topotecan, Cyclophosphamide
Age
2 - 21 years
Phase
I
Conditions: Arthritis
Drugs: Ixekizumab, Adalimumab
Age
2 - 17 years
Phase
III